Exploration of Targeted Anti-tumor Therapy

Name of test	Mutation	Drugs	Technology	Limit of detection
Cobas EGFR mutation test v2	EGFR exon 19 deletion EGFR L858R EGFR T790M EGFR uncommon mutations	Gefitinib, erlotinib, osimertinib	RT-PCR	5% [7]
Gurdant 360 CDx	EGFR mutations EGFR exon 20 insertion KRAS Gly12Cys	Osimertinib, amivantamab, sotorasib	NGS panel (61 genes)	0.25% [8] 1.50% (package insert)
FoundationOne Liquid CDx	EGFR mutations (exon 19 deletion, L858R) ALK fusion MET exon 14 skipping	Gefitinib, erlotinib, osimertinib, alectinib, capmatinib	NGS panel (318 genes)	0.27∼0.94% [9]
ArcherMET	MET exon 14 skipping	Tepotinib	NGS	0.20% (package insert) [10]

Name of test

Mutation

Drugs

Technology

Limit of detection

Cobas EGFR mutation test v2

EGFR exon 19 deletion
EGFR L858R
EGFR T790M
EGFR uncommon mutations

Gefitinib, erlotinib, osimertinib

RT-PCR

5% [7]

Gurdant 360 CDx

EGFR mutations
EGFR exon 20 insertion
KRAS Gly12Cys

Osimertinib, amivantamab, sotorasib

NGS panel (61 genes)

0.25% [8]
1.50% (package insert)

FoundationOne Liquid CDx

EGFR mutations (exon 19 deletion, L858R)
ALK fusion
MET exon 14 skipping

Gefitinib, erlotinib, osimertinib, alectinib, capmatinib

NGS panel (318 genes)

0.27∼0.94% [9]

ArcherMET

MET exon 14 skipping

Tepotinib

NGS

0.20% (package insert) [10]